Yarema Kristin 4

What Happened
Kristin Yarema, CEO of ImageneBio, received two equity awards on March 16, 2026: 85,400 restricted stock units (RSUs) and 128,100 derivative shares (an option-style award). Both grants are listed at $0.00 acquisition price (i.e., they are compensation awards, not purchases). Total awarded shares equal 213,500. These are grants (code A), not sales or exercises.

Key Details

• Transaction date: 2026-03-16; Form 4 filed 2026-03-18 (appears timely — Form 4 is due within 2 business days).
• 85,400 RSUs acquired at $0.00 (footnote F1). RSUs convert to one share each upon settlement.
• 128,100 derivative shares acquired at $0.00 (footnote F2) — an option-style grant that vests over time.
• Vesting (F1): RSUs — 25% vest/settle on March 15, 2027; remaining balance vests in equal quarterly installments on the next 12 Standard Quarterly Dates (March 15, June 15, Sept 15, Dec 15).
• Vesting (F2): Option-style award — 25% vests on March 15, 2027; remaining shares vest in 36 substantially equal monthly installments (four-year schedule).
• Shares owned after transaction: Not specified in the provided filing.
• Transaction codes: A = Award/Grant; the 128,100 item is a derivative award (not an exercise).

Context
These are compensation grants to the CEO and do not involve a cash purchase or an immediate sale of shares. Grants are common for executive pay and are tied to continued service (and possibly performance); they do not necessarily signal a near-term market view. The option-style award has a multi-year vesting schedule and has not been exercised.